Literature DB >> 17003405

Uncoordinated expression of myosin heavy chains and myosin-binding protein C isoforms in human extraocular muscles.

Daniel Kjellgren1, Per Stål, Lars Larsson, Dieter Fürst, Fatima Pedrosa-Domellöf.   

Abstract

PURPOSE: To examine the distribution of myosin-binding protein C (MyBP-C) in human extraocular muscles (EOMs) and to correlate the myosin heavy chain (MyHC) and the MyBP-C composition of the fibers.
METHODS: Samples from 17 EOMs, 3 levator palpebrae (LP), and 6 limb muscles were analyzed with SDS-PAGE and immunoblot or processed for immunocytochemistry with monoclonal antibodies (mAbs) against MyBP-C-fast, MyBP-C-slow, MyHCIIa, MyHCI, MyHCsto, MyHCalpha-cardiac, and MyHCemb.
RESULTS: In the limb muscle samples, fast fibers were labeled with anti-MyBP-C-fast and anti-MyBP-C-slow, whereas the slow fibers were immunostained with anti-MyBP-C-slow only, in accordance with previous studies. In 11 EOM samples MyBP-C-fast was not detected, and weak staining with anti-MyBP-C-fast was seen only in a few fibers in the proximal part of 2 muscles. The mAb against MyBP-C-slow labeled all fibers, but fibers containing MyHCI were generally more strongly stained. In the levator palpebrae, immunostaining with anti-MyBP-C-fast was present in some fibers labeled with anti-MyHCIIa and/or anti-MyHCeom. MyBP-C-fast and -intermediate were not detected biochemically in the EOMs.
CONCLUSIONS: The lack of MyBP-C-fast and intermediate is an additional feature of the human EOM allotype. The true EOMs have a unique myofibrillar protein isoform composition reflecting their special structural and functional properties. The levator palpebrae muscle phenotype is intermediate between that of the EOMs and the limb muscles.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17003405     DOI: 10.1167/iovs.05-1496

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  9 in total

1.  Distinctive patterns of microRNA expression in extraocular muscles.

Authors:  Ulrike Zeiger; Tejvir S Khurana
Journal:  Physiol Genomics       Date:  2010-02-09       Impact factor: 3.107

2.  Wnt and extraocular muscle sparing in amyotrophic lateral sclerosis.

Authors:  Linda K McLoon; Vahid M Harandi; Thomas Brännström; Peter M Andersen; Jing-Xia Liu
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-08-14       Impact factor: 4.799

3.  A novel MYH2 mutation in family members presenting with congenital myopathy, ophthalmoplegia and facial weakness.

Authors:  Tracey Willis; Carola Hedberg-Oldfors; Zoya Alhaswani; Richa Kulshrestha; Caroline Sewry; Anders Oldfors
Journal:  J Neurol       Date:  2016-05-13       Impact factor: 4.849

4.  A continuum of myofibers in adult rabbit extraocular muscle: force, shortening velocity, and patterns of myosin heavy chain colocalization.

Authors:  Linda K McLoon; Han Na Park; Jong-Hee Kim; Fatima Pedrosa-Domellöf; Ladora V Thompson
Journal:  J Appl Physiol (1985)       Date:  2011-07-21

5.  Unique expression of cytoskeletal proteins in human soft palate muscles.

Authors:  Farhan Shah; Diana Berggren; Thorbjörn Holmlund; Eva Levring Jäghagen; Per Stål
Journal:  J Anat       Date:  2015-11-24       Impact factor: 2.610

6.  Development transitions of thin filament proteins in rat extraocular muscles.

Authors:  Carole L Moncman; Miguel E Andrade; Andrea A McCool; Colleen A McMullen; Francisco H Andrade
Journal:  Exp Cell Res       Date:  2012-11-19       Impact factor: 3.905

7.  Ocular myositis: diagnostic assessment, differential diagnoses, and therapy of a rare muscle disease - five new cases and review.

Authors:  Benedikt G H Schoser
Journal:  Clin Ophthalmol       Date:  2007-03

8.  A rare case of ocular myositis.

Authors:  Carmen Valeria Albu; B Cătălin; Cornelia Zaharia
Journal:  Curr Health Sci J       Date:  2013-12-29

9.  Histochemical and immunohistochemical profile of human and rat ocular medial rectus muscles.

Authors:  Branka Stirn Kranjc; Vika Smerdu; Ida Erzen
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2009-07-17       Impact factor: 3.117

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.